Artificial Intelligence is Ramping up in Drug Development BioSpace

AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence. The two companies will focus on using AI and machine learning to discover and develop new drugs for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). "The vast amount of data available to research scientists is growing exponentially each year," stated Mene Pangalo, AstraZeneca's executive vice president and president BioPharmaceuticals R&D. "By combining AstraZeneca's disease area expertise and large, diverse datasets with BenevolentAI's leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases." No financial details were disclosed.